Parkinson’s disease (PD) is the second most common neurodegenerative disorder, yet early and accurate diagnosis remains a challenge. Blood-based biomarkers offer a minimally invasive solution to detect and monitor PD, paving the way for improved patient outcomes and accelerated drug development.
Download our latest application note, “Advancing Parkinson’s Disease Research: The Role of Blood-Based Biomarkers,” to explore:
- The urgent need for reliable PD biomarkers and their role in early detection
- Key biomarkers, including alpha-synuclein (α-syn), NfL, GFAP, and inflammatory markers
- How ultra-sensitive Simoa® technology enables precise biomarker quantification in blood
- The impact of blood biomarkers on drug development and patient stratification
Gain Insights from Cutting-Edge Biomarker Research
Learn how the latest advancements in biomarker detection can transform Parkinson’s disease research and clinical care. Download the application note now to stay at the forefront of innovation.
Download the app note to learn more
Related Posts
Mapping the Tau Cascade: New Insights from p-Tau 205 and p-Tau 212 for Disease Staging and Monitoring
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…